How does tigecycline's patent status affect its pricing?

Tigecycline's current patent status keeps it off the generic market and sustains its brand-name pricing.

When does tigecycline's patent expire?
Tigecycline's composition-of-matter patent expired in 2014. The main remaining protection comes from regulatory exclusivity tied to its approval as a new molecular entity. That exclusivity ended in 2011. Both forms of intellectual property protection have lapsed, yet generic versions did not appear until 2020.

Why did generics enter only after 2020?
Multiple patents listed in the FDA Orange Book for formulation, method of use, and manufacturing processes still blocked early entry. Manufacturers had to design around these patents or wait for their expiry. The delay kept supply low and prices elevated for years after core protection ended.

What keeps prices high now?
Tigecycline remains expensive even though generics are available. Market concentration plays a role. Only a few manufacturers hold FDA approvals, including Pfizer for the brand Tygacil and limited generic entrants. Supply disruptions have also occurred. Supply chain issues and manufacturing complexities for this antibiotic affect availability, and therefore price.

Can lower-priced generics replace the brand?
Tigecycline generics cost far less than Tygacil. The brand still sells at a premium, but many hospitals turn to cheaper alternatives once quality is verified. Quality concerns with some imported generics have slowed substitution in certain facilities.

Who makes the generics?
Several companies produce generic tigecycline. Among them is Pfizer itself through its Hospira subsidiary. Other entrants include The Medicines Company, The Greenstone LLC, and several Indian manufacturers exporting to the U.S. under FDA-approved methods.

When does the last listed patent expire?
The letzten listed patent in the FDA Orange Book expires in 2026. This small rest of protection keeps some manufacturers cautious and sustains a semi-exclusive market segment.